Epidermal growth factor receptor‐targeted treatment for advanced colorectal carcinoma

Substantial effort has focused on the development of novel targeted agents for treating patients with late‐stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor recept...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2005-06, Vol.103 (12), p.2435-2446
Main Author: Venook, Alan P.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
bevacizumab
Biological and medical sciences
cetuximab
colorectal carcinoma
Colorectal Neoplasms - drug therapy
epidermal growth factor receptor
Gastroenterology. Liver. Pancreas. Abdomen
Humans
IMC‐C225
Medical sciences
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - physiology
Signal Transduction
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
targeted chemotherapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Substantial effort has focused on the development of novel targeted agents for treating patients with late‐stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma. Cancer 2005. © 2005 American Cancer Society. An in‐depth status report on epidermal growth factor receptor‐targeted agents for the treatment of patients with late‐stage colorectal carcinoma is provided.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.21123